EA201070540A1 - Многоцелевые соединения, активные в отношении ppar и каннабиноидных рецепторов - Google Patents

Многоцелевые соединения, активные в отношении ppar и каннабиноидных рецепторов

Info

Publication number
EA201070540A1
EA201070540A1 EA201070540A EA201070540A EA201070540A1 EA 201070540 A1 EA201070540 A1 EA 201070540A1 EA 201070540 A EA201070540 A EA 201070540A EA 201070540 A EA201070540 A EA 201070540A EA 201070540 A1 EA201070540 A1 EA 201070540A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ppar
pharmacophore
cannabinoid
compounds
condensed
Prior art date
Application number
EA201070540A
Other languages
English (en)
Inventor
Пьер Десремо
Сальваторе Беллинвия
Филипп Шаватт
Серджо Барони
Original Assignee
Джулиани Интернэшнл Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джулиани Интернэшнл Лимитед filed Critical Джулиани Интернэшнл Лимитед
Publication of EA201070540A1 publication Critical patent/EA201070540A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Существует потребность в фармацевтических соединениях, которые обладают активностью по меньшей мер, на одном из PPAR и каннабиноидных рецепторов. Таким образом, обеспечены такие соединения, где соединение включает PPAR-фармакофор и каннабиноидный фармакофор, связанные вместе через фрагмент, содержащий конденсированную бициклическую систему, включающую пятичленный цикл, конденсированный с шестичленным циклом, или шестичленный цикл, конденсированный с шестичленным циклом; где каннабиноидный фармакофор содержит конденсированный бициклический фрагмент; и PPAR-фармакофор содержит функциональность салициловой кислоты, алкоксибензилуксусной кислоты или алкоксифенилуксусной кислоты; и где PPAR-фармакофор связан с бициклическим фрагментом каннабиноидного фармакофора через линкер, содержащий аминную или амидную функциональную группу.
EA201070540A 2007-12-21 2008-12-22 Многоцелевые соединения, активные в отношении ppar и каннабиноидных рецепторов EA201070540A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE20070928A IE20070928A1 (en) 2007-12-21 2007-12-21 Multi target ligands
PCT/EP2008/068205 WO2009080821A2 (en) 2007-12-21 2008-12-22 Receptor targeting ligands

Publications (1)

Publication Number Publication Date
EA201070540A1 true EA201070540A1 (ru) 2010-12-30

Family

ID=40801618

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070540A EA201070540A1 (ru) 2007-12-21 2008-12-22 Многоцелевые соединения, активные в отношении ppar и каннабиноидных рецепторов

Country Status (15)

Country Link
US (1) US20110039808A1 (ru)
EP (1) EP2222287A2 (ru)
JP (1) JP2011506581A (ru)
KR (1) KR20100098375A (ru)
CN (1) CN101878027B (ru)
AU (1) AU2008339902A1 (ru)
BR (1) BRPI0820568A2 (ru)
CA (1) CA2704268A1 (ru)
EA (1) EA201070540A1 (ru)
IE (1) IE20070928A1 (ru)
IL (1) IL205669A0 (ru)
MX (1) MX2010005905A (ru)
NZ (1) NZ585326A (ru)
WO (1) WO2009080821A2 (ru)
ZA (1) ZA201002954B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
EA030762B1 (ru) 2012-02-09 2018-09-28 Ногра Фарма Лимитед Способы лечения фиброза
WO2015062825A1 (en) * 2013-10-29 2015-05-07 Sabic Global Technologies B.V. Glass fibre reinforced polyolefin composition
CN105764660A (zh) 2013-11-15 2016-07-13 Sabic环球技术有限责任公司 用于生产玻璃纤维-增强热塑性聚合物组合物的方法
BR112016022240B1 (pt) 2014-03-31 2021-08-17 Sabic Global Technologies B.V. Métodos para a fabricação de polipropileno de baixa emissão, composição termoplástica e artigo interior automotivo
CN107206631B (zh) 2014-11-27 2019-07-23 Sabic环球技术有限责任公司 长玻璃纤维增强的聚丙烯组合物的生产方法
EP3230029B1 (en) 2014-12-08 2020-04-29 SABIC Global Technologies B.V. Process for the manufacture of glass fibre reinforced pellets
WO2016174232A1 (en) 2015-04-29 2016-11-03 Sabic Global Technologies B.V. Mass transit vehicle component
WO2016198344A1 (en) 2015-06-12 2016-12-15 Sabic Global Technologies B.V. Process for manufacture of low emission polypropylene
CN106924272B (zh) * 2015-12-31 2021-04-13 中国医学科学院药物研究所 水杨酸甲酯糖苷在制备预防和/或治疗系统性红斑狼疮及其并发症药物中的用途
WO2017139044A1 (en) * 2016-02-09 2017-08-17 Albert Einstein College Of Medicine, Inc. Residue-based pharmacophore method for identifying cognate protein ligands
WO2018017573A1 (en) 2016-07-21 2018-01-25 Sabic Global Technologies B.V. Flame retardant glass-filled polypropylene compositions and articles formed from the same
EP3551674A1 (en) 2016-12-12 2019-10-16 SABIC Global Technologies B.V. Process for manufacture of low emission homopolymer or random polypropylene
CN110198963B (zh) 2016-12-12 2022-06-24 Sabic环球技术有限责任公司 制造低排放异相聚丙烯的方法
US11273884B2 (en) 2018-09-05 2022-03-15 Sabic Global Technologies B.V. Bicycle frame
WO2020161362A1 (en) 2019-02-08 2020-08-13 Nogra Pharma Limited Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0195582B1 (en) * 1985-03-14 1990-01-24 SMITH KLINE DAUELSBERG GmbH 5-aminosalicylic acid derivatives of non-steroidal antiinflammatory acids
DE3812755A1 (de) * 1988-04-16 1989-10-26 Merck Patent Gmbh Salicylsaeurederivate
US5502035A (en) * 1993-08-06 1996-03-26 Tap Holdings Inc. N-terminus modified analogs of LHRH
US5413990A (en) * 1993-08-06 1995-05-09 Tap Pharmaceuticals Inc. N-terminus modified analogs of LHRH
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5532237A (en) * 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
WO1999005161A1 (en) * 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
JP2000256323A (ja) * 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
CN1164574C (zh) * 1999-05-24 2004-09-01 三菱制药株式会社 苯氧基丙胺类化合物
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
MXPA02005101A (es) * 1999-10-18 2003-09-25 Alexipharma Inc Derivados de indol canabimimeticos.
JPWO2001085693A1 (ja) * 2000-05-11 2004-01-08 萬有製薬株式会社 Ｎ−アシルテトラヒドロイソキノリン誘導体
GB0028702D0 (en) * 2000-11-24 2001-01-10 Novartis Ag Organic compounds
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
FR2833949B1 (fr) * 2001-12-21 2005-08-05 Galderma Res & Dev NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS PPARy, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE
US20040171613A1 (en) * 2001-12-27 2004-09-02 Japan Tobacco Inc. Therapeutic agent for non-immediate type allergic diseases
WO2003061699A1 (fr) * 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedes pour affections allergiques
WO2003091213A1 (fr) * 2002-04-25 2003-11-06 Yamanouchi Pharmaceutical Co., Ltd. Derives d'amide ou sels de ces derives
US20050101542A1 (en) * 2002-08-20 2005-05-12 Regents Of The University Of California Combination therapy for controlling appetites
AU2003303376A1 (en) * 2002-12-19 2004-07-22 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
WO2004058683A2 (en) * 2002-12-20 2004-07-15 Migenix Corp. Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
JP2006523196A (ja) * 2003-03-11 2006-10-12 ニューロサーチ、アクティーゼルスカブ 新規ｋｃｎｑチャネルを調節する化合物及びその医薬用途
BRPI0411674A (pt) * 2003-06-20 2006-08-29 Galderma Res & Dev compostos, composição cosmética, uso cosmético de uma composição, uso de um composto, composição farmacêutica, e processo cosmético para o embelezamento da pele
US20070093476A1 (en) * 2003-10-28 2007-04-26 Bhunia Debnath Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
JP2005162657A (ja) * 2003-12-02 2005-06-23 Takeda Chem Ind Ltd カンナビノイド受容体調節剤
EP1773771A2 (en) * 2004-07-23 2007-04-18 Daiamed, Inc. Compounds and methods for treatment of thrombosis
AR050631A1 (es) * 2004-09-09 2006-11-08 Novartis Ag Combinacion de compuestos organicos
CN1955175A (zh) * 2004-10-28 2007-05-02 中国医学科学院药物研究所 香豆素衍生物及其制法和其药物组合物与用途
EP1770091A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1937243A2 (en) * 2005-10-18 2008-07-02 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Naphthyl derivatives as inhibitors of beta-amyloid aggregation
WO2007081910A2 (en) * 2006-01-05 2007-07-19 Kinemed, Inc. Compositions and methods of treatment using modulators of motonueron diseases
WO2007124617A1 (fr) * 2006-04-28 2007-11-08 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations
CA2663347A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20080221161A1 (en) * 2007-02-09 2008-09-11 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease

Also Published As

Publication number Publication date
KR20100098375A (ko) 2010-09-06
NZ585326A (en) 2012-07-27
BRPI0820568A2 (pt) 2015-06-16
AU2008339902A1 (en) 2009-07-02
ZA201002954B (en) 2011-08-31
IE20070928A1 (en) 2009-09-30
CN101878027A (zh) 2010-11-03
WO2009080821A3 (en) 2010-01-14
CN101878027B (zh) 2013-01-16
IL205669A0 (en) 2010-11-30
JP2011506581A (ja) 2011-03-03
US20110039808A1 (en) 2011-02-17
CA2704268A1 (en) 2009-07-02
WO2009080821A2 (en) 2009-07-02
EP2222287A2 (en) 2010-09-01
MX2010005905A (es) 2010-10-05

Similar Documents

Publication Publication Date Title
EA201070540A1 (ru) Многоцелевые соединения, активные в отношении ppar и каннабиноидных рецепторов
EA201170742A1 (ru) Производные n-{[(1r,4s,6r)-3-(2-пиридинилкарбонил)-3-азабицикло[4.1.0]гепт-4-ил]метил}-2-гетероариламинов и их применения
EA201590979A1 (ru) Способы и промежуточные химические соединения для получения фармацевтических средств
SMT201400142B (it) Composti di N-(1H-indazol-4-il) immidazo[1,2-A]piridin-3-carbossammide sostituita come inibitori di cfms
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
MX2010003259A (es) Ensayo de monitoreo de farmacos.
UY32276A (es) Derivados de n-{[1s,4s,6s)-3-(2-piridinilcarbonil)-3-azabiciclo[4.1.0]hept-4-il}metil}-2heteroarilamina y uso de los mismos
EA201070451A1 (ru) Амидные соединения
FR2921928B1 (fr) Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
MA35172B1 (fr) Melanges pestticides contenant des derives d'isoxazoline
EA200970247A1 (ru) Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
EA200802380A1 (ru) Совместные кристаллы пирролидинонов
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
EA201491658A1 (ru) Таблетки для комбинированной терапии
EA201491002A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
EA201101147A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
EA200971044A1 (ru) Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
RS52108B (en) 3-SUBSTITUTED [1,2,3] -BENZOTRIAZINONE UNIT TO INCREASE GLUTAMATERGIC SYNAPTIC ANSWERS
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
DOP2009000088A (es) Pirazoles sustituidos que presentan actividad anticancerígena
FR2925332B1 (fr) Utilisation d'un hydrolysat d'epeautre en tant que principe actif activateur de la synthese des aquaporines
EA201000398A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
EA200700364A1 (ru) Производные амида кинуреновой кислоты как антагонисты nr2b подтипа рецептора nmda
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
ME01144B (me) 3-aminociklopentankarboksamidi kao modulatori hemokin receptora